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Abstract  
Dapsone is a leprostatic agent routinely used for malaria and leprosy. It is also used as a 
prophylaxis for pneumocystis jiroveci pneumonia (PCP), as well as for toxoplasma gondii in 
immunocompromised patients. Methemoglobinemia is an adverse effect of dapsone and can be 
life-threatening. Detailed is a case of dapsone-induced methemoglobinemia in a young woman 
with lupus nephritis who was treated with chronic immunosuppressant medications.  
Keywords 
Dapsone, Methemoglobinemia, Intravascular Hemolysis 
Introduction 
Dapsone is a synthetic sulfone that inhibits folate synthesis. The adverse effects of dapsone may 
occur after few days of drug consumption. Acute adverse effects include nausea, vomiting, 
abdominal pain, methemoglobinemia, seizure, and coma; chronic adverse effects include 
eosinophilic pneumonia, aplastic anemia, hemolysis, neuropathy, hepatitis and agranulocytosis. 
Methemoglobinemia may be acute or chronic, while hemolytic anemia occurs after chronic 
consumption of dapsone. In this article, we report a rare combination of Dapsone-induced 
methemoglobinemia and hemolytic anemia in a patient with lupus nephritis and normal G6PD 
level.1 
Case Presentation  
Initial Presentation and history 
A 22-year-old woman with an 8-year history of stage IV lupus nephritis presented to the 
emergency department with hypertensive emergency. Upon admission, blood pressure was 
recorded as 220/116 mmHg and anasarca was documented. Review of systems was remarkable 
for arthralgia. Current home medications included hydroxychloroquine 200 mg daily, lisinopril 
2.5 mg daily, aspirin 81 mg daily, mycophenolate mofetil 1000 mg twice a day and 
methylprednisolone 4 mg daily. She was compliant with all of her medications except for 
mycophenolate mofetil. Allergy to sulfa antibiotics was reported. Physical examination revealed 
blood pressure of 220/116 mmHg and heart rate of 119 bpm. Integumentary exam noted malar 
rash, conjunctival injection, pitting edema and petechiae on lower extremities.  Abdominal exam 
noted tenderness in right upper quadrant without rebound or guarding. Clinically significant 
laboratory tests are shown in Table 1.  
Hospital Course 
The patient was admitted for hypertensive emergency. Blood pressure was controlled with 
intravenous nicardipine and lisinopril. Nephrology was consulted for blood pressure control and 
management of possible exacerbation of lupus nephritis.  The clinical presentation along with 
active urinary sediment in addition to recent interruption of immunosuppressive therapy 
suggested relapse of lupus nephritis. Documentation of marked hypocomplementemia and high 
titer Anti-DS-DNA as shown in Table 1 also supported exacerbation of lupus nephritis. 
Treatment initially consisted of pulse dose methylprednisolone (500 mg IV day 1-3), dapsone 
100 mg daily for PCP prophylaxis, in addition to mycophenolate mofetil 1000 mg twice daily. 
Acute anemia was noted on hospital day six with a symptomatic drop in hemoglobin from 12.4 
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g/dl on the day of admission down to 6.9 g/dl. Thrombocytopenia and acute renal insufficiency 
were noted with platelet count of 75 and an elevation in creatinine as respectively noted in Table 
1. Physical exam noted a pulse oximetry of 80% but was otherwise unremarkable. Chest 
radiograph did not show evidence of pulmonary vascular congestion.  
Hemolysis work up showed significantly elevated lactate dehydrogenase (LDH) level, low 
haptoglobin and high reticulocyte count. Peripheral blood smear showed slight anisocytosis, 
occasional ovalocytes, macrocytes, and schishtocytes.  
In the setting of immunologically active SLE and lupus nephritis, the intravascular hemolysis 
along with thrombocytopenia and acute kidney injury suggested the presence of 
microangiopathic hemolytic anemia (MAHA) particularly, antiphospholipid syndrome (APS) or 
thrombotic thrombocytopenic purpura (TTP). On the other hand, the low level of oxygen 
saturation at rest in spite of oxygen supplementation along with the absence of clinical and 
radiological evidence of pulmonary edema suggested an oxygen dissociation curve disorder. This 
was further confirmed by arterial blood gas (ABG) analysis showing oxygen saturation gap (pH, 
7.41; Paco2,29 mm Hg; Pao2 156 mmHg; bicarbonate, 18.7mEq/L; base excess 5.4mEq/L. and 
Oxygen saturation, 80% on 4L/min by nasal cannula).   
Considering the ABG results, the clinical condition and recent dapsone therapy, 
methemoglobinemia was confirmed by plasma methemoglobin level of 17.9%. Proceeding 
confirmation of methemoglobinemia, treatment commenced with intravenous methylene blue. 
DISCUSSION  
Dapsone and Methemoglobinemia 
Dapsone is a sulfone antibiotic and potent anti-inflammatory that inhibits folate synthesis. 
Although an antileprosy drug, its use has expanded into the treatment of dermatologic 
conditions, including pyoderma gangrenosum, bullous systemic lupus erythematosus, and 
dermatitis herpetiformis and also as prophylaxis for pneumocystis jiroveci pneumonia.1  Dapsone 
is metabolized in the liver via the cytochrome P450 pathway to potent oxidants that are 
responsible for its adverse effects; hemolytic anemia and methemoglobinemia.  
Methemoglobin is an aberrant form of hemoglobin arising from oxidation of iron in the normal 
heme molecule from the ferrous form (Fe2+) to the ferric form (Fe3+). The presence of ferric 
heme molecules causes a structural change in the hemoglobin molecule, resulting in reduced 
oxygen carrying capacity and impaired unloading of oxygen at the tissue. This results in 
functional anemia.2 
 
Normally, red blood cells maintain a steady-state methemoglobin level of less than 1%. 
Elevation in methemoglobin levels can be caused by congenital enzyme deficiencies or exposure 
to exogenous oxidizing agents. Several exogenous oxidizing agents are known to cause acquired 
methemoglobinemia. Dapsone is the medication that most commonly causes 
methemoglobinemia, but other offending drugs include the local anesthetics benzocaine and 
lidocaine.  There is a paucity of literature regarding the incidence of dapsone-induced 
methemoglobinemia for P jiroveci pneumonia prophylaxis.3 
Clinical symptoms of methemoglobinemia depend on the serum concentration of 
methemoglobin. Peripheral and central cyanosis are usually seen at a serum methemoglobin level 
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of 15%. Methemoglobin levels of 30% to 45% result in headache, fatigue, tachycardia, 
weakness, and dizziness, while levels above 60% result in cardiac arrhythmia, dyspnea, seizures, 
and coma. Death typically occurs at methemoglobin levels greater than 70%.1   
Definitive diagnosis of methemoglobinemia is based on an elevated serum methemoglobin level. 
However, serum methemoglobin levels are not always immediately available. Therefore, clinical 
suspicion in presence of the oxygen “saturation gap” between arterial blood gas analysis and 
pulse oximetry readings is helpful in making clinical diagnosis of methemoglobinemia.4  Pulse 
oximetry can only measure oxyhemoglobin and reduced hemoglobin.5  As other hemoglobins 
such as methemoglobin rise, the oxygen saturation on pulse oximetry falls and plateaus at 85%.5 
This saturation gap, where oxygen saturation levels measured with pulse oximetry are 
substantially lower than arterial blood gas oxygen saturation levels, should alert the practitioner 
to presence of methemoglobinemia. Also, in cases of methemoglobinemia, arterial blood samples 
will be a characteristic chocolate-brown colour.6 
In addition to oxidation of heme iron, dapsone’s metabolites induce erythrocyte destruction by 
the formation of reactive oxygen species. The primary defense against oxidative injury in 
erythrocytes is the glucose-6-phosphate dehydrogenase (G6PD)–NADPH–glutathione pathway, 
which neutralizes free radicals. In patients with G6PD deficiency, dapsone causes severe 
hemolysis, since less reduced glutathione is available to handle the oxidative injury.7 Unlike 
substances that cause hemolysis only in persons with G6PD deficiency, dapsone can cause 
hemolysis in patients with normal G6PD levels. This patient had elevated hemolysis markers, 
including unconjugated hyperbilirubinemia, an elevated lactate dehydrogenase level, low 
haptoglobin level, and reticulocytosis despite of normal G6PD level. 
Initial management of patients with methemoglobinemia is immediate discontinuation of the 
offending agent. For patients with signs of hypoxia or methemoglobin levels exceeding 30%, 
administration of intravenous methylene blue at 1 to 2 mg/kg is indicated.1  Methylene blue is 
reduced by NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) to act as an 
artificial electron donor to methemoglobin, thereby enhancing the erythrocyte’s ability to reduce 
methemoglobin. If symptoms persist,  repeat doses of methylene blue can be given with caution, 
as accumulation of the drug can result in increased production of methemoglobin.8  If symptoms 
persist despite adequate therapy, hemodialysis might be required. 
In our patient, the presence of MAHA in the setting of immunologically active lupus nephritis 
initially suggested the existence of APL or TTP, two life threatening and well known conditions 
to develop in active lupus patients. High index of suspicion and rapid diagnosis was necessary in 
order to plan active therapy that can include plasma exchange. On the other hand, the oxygen 
saturation gap prompted the consideration and diagnosis of methemoglobinemia. Arterial blood 
gas analysis in this case was essential in differentiating between the causes of MAHA. 
CONCLUSION 
  
Patients receiving dapsone are at risk of developing methemoglobinemia.  Methemoglobinemia 
is a medical emergency that may result in death if not detected and promptly treated. Successful 
diagnosis and treatment require high index of suspicion. Occurrence of cyanosis or unexplained 
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decrease in oxygen saturation should alert the medical team to the possibility of 
methemoglobinemia. An ABG should be performed when methemoglobinemia is suspected and 
the offending agent should be discontinued. 9 
 
 
Table 1: Laboratory Results 
 
Event Day 1 Day 6 Day 7 Ref. Range 
WBC 6.4 12.3 14 4.5-10 
Hgb 12.4 6.9 10.0 12.0-16.0 
Platelet 145 75 95 150-440 
Potassium 4.5 5.0 5.1 3.5-5.0 
Sodium 152 142 136 135-145 
Creatinine 0.97 2.13 2.16 0.6-1.10 
BUN 23 89 91 7-21 
Reticulocytes 
count 
 3.7  0.7-3.1 
LDH  752 652 100-190 
Haptoglobin  <7  32-145 
Complement 
C3, Serum 
 28  90-180   
mg/dL 
Complement 
C4, Serum 
 8  9-36     mg/dL 
Anti-DNA (DS) 
Ab 
 >300  <5   IU/mL 
Methemoglobin  17.9, 4.7, 
4.5 
3.6  
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